Abstract:
A crucial component of the immune system are chemokiness. Chemokine\'s dysregulation has been linked to a number of pathological diseases. Recently, CXCL17, a chemokine belonging to the CXC subfamily, was identified. With regard to a number of physiological conditions and disorders, CXCL17 either has homeostatic or pathogenic effects. Some research suggests that CXCL17 is an orphan ligand, despite the fact that G protein-coupled receptor (GPR) 35 has been suggested as a possible receptor for CXCL17. Since CXCL17 is primarily secreted by mucosal epithelia, such as those in the digestive and respiratory tracts, under physiological circumstances, this chemokine is referred to as a mucosal chemokine. Macrophages and monocytes are the cells that express GPR35 and hence react to CXCL17. In homeostatic conditions, this chemokine has anti-inflammatory, antibacterial, and chemotactic properties. CXCL17 promotes angiogenesis, metastasis, and cell proliferation in pathologic circumstances like malignancies. However, other studies suggest that CXCL17 may have anti-tumor properties. Additionally, studies have shown that CXCL17 may have a role in conditions such as idiopathic pulmonary fibrosis, multiple sclerosis, asthma, and systemic sclerosis. Additionally, deregulation of CXCL17 in some diseases may serve as a biomarker for diagnosis and prognosis. Clarifying the underlying mechanism of CXCL17\'s activity in homeostatic and pathological situations may thus increase our understanding of its role and hold promise for the development of novel treatment strategies.
摘要:
免疫系统的一个重要组成部分是趋化因子。趋化因子的失调与许多病理疾病有关。最近,CXCL17,一种属于CXC亚家族的趋化因子,已确定。关于一些生理状况和疾病,CXCL17具有稳态或致病作用。一些研究表明,CXCL17是一个孤儿配体,尽管G蛋白偶联受体(GPR)35已被认为是CXCL17的可能受体。由于CXCL17主要由粘膜上皮分泌,比如消化道和呼吸道,在生理情况下,这种趋化因子被称为粘膜趋化因子。巨噬细胞和单核细胞是表达GPR35并因此与CXCL17反应的细胞。在稳态条件下,这种趋化因子具有抗炎作用,抗菌,和趋化特性。CXCL17促进血管生成,转移,和恶性肿瘤等病理环境中的细胞增殖。然而,其他研究表明CXCL17可能具有抗肿瘤特性。此外,研究表明,CXCL17可能在特发性肺纤维化等疾病中发挥作用,多发性硬化症,哮喘,和系统性硬化症。此外,CXCL17在某些疾病中的失调可能作为诊断和预后的生物标志物。因此,阐明CXCL17在稳态和病理情况下的活性的潜在机制可能会增加我们对其作用的理解,并有望开发新的治疗策略。